Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

Cascade Investment

T. Rowe Price

Viking Global Investors

Illumina

Ginkgo Bioworks, Inc.

Today on Foundry Theory we're all about iGEM - the heart of synthetic biology.
https://hubs.la/Q02kdx3q0

Humans of Ginkgo Bioworks is an interview series, featuring Sudeep Agarwala, that dives into the exciting technology at Ginkgo.

Today, we've released the final part of our three-part interview with Ginkgo’s head of ALE, Simon Trancart!

In Part 3, Simon discusses how our partners are working with us to make automated ALE at Ginkgo accessible to new industries.

Read it here:
https://hubs.la/Q02k9M_00

Catch up on Part 1 here: https://hubs.la/Q02k9Pbj0

And Part 2 here: https://hubs.la/Q02k9M8z0

Thank you, Elaine Watson and AgFunder, for the great featuring of our offering and strategic collaborations with Ginkgo Bioworks, Inc. and dsm-firmenich toward launching our products.

Tal Zeltzer | Sandro Tomita | Fredrik Hjelmqvist | David Borhani | Kevin Madden

#DOD Biomanufacturing RFP is out 👇🏻👇🏻 

https://lnkd.in/e6Bk8jtW

When I started my NSC detail, I knew very little about #biomanufacturing but after drinking from a firehose on the topic for a few months I came to see the plethora of ways this growing ecosystem of bio companies and technologies can strengthen America; from improving sustainability, strengthening supply chains, and growing the economy.

This RFP is an opportunity to invest in building Biomanufacturing capacity across the country. It's great to see it posted.

Congrats to all the people who worked hard to get this done: Kate Sixt Peter Emanuel Michelle Rozo Kirsten Kulcsar Weand, PhD Anne Cheever Georgia Lagoudas Sarah Glaven Douglas Friedman Robert Fisher Ben Buchanan Ishan K. Sharma and many others.

Check out Nita Madhav and friends as they figure out how to ensure we don't have another major biological event in our lifetimes. https://lnkd.in/eN94t7_F

Die Teilnehmer*innen der Delegationsreise in die USA hatte die Gelegenheit, Ginkgo Bioworks, Inc. zu besuchen und einen Einblick in deren Entwicklung und Labors zu erhalten.

Ginkgo Bioworks ist ein Biotech-Unternehmen, das sich auf die gentechnische Herstellung von Bakterien für industrielle Anwendungen spezialisiert hat. Die Expertise des Unternehmens erstreckt sich über die Entwicklungen von Mikroorganismen bis hin zur Herstellung von synthetischen Zellen, die schließlich die Grundlage für die Produktion verschiedener Materialien bilden können.

Der Besuch ermöglichte es neueste Fortschritte und Innovationen im Bereich der Genomtechnologie zu erkunden. Die Labors boten Einblicke in die Präzisionsarbeit, die hinter der Entwicklung maßgeschneiderter Mikroorganismen steht. Philipp Heuermann zeigten die internationalen Perspektiven von Ginkgo Bioworks auf.

VDMA, Wittenstein Stiftung, Universität Hohenheim, Universität Stuttgart, Baden-Württemberg International (BW_i), Thomas Bauernhansl

This is biology's century.

Just as computer science transformed the 20th century, biological science will transform the 21st. 

Alison Snyder explores growing global competition to harness that science to develop and make biotechnology products at scale.

More in In Axios Science👇🏾 

https://lnkd.in/eakijuky

“Biology is the only substrate, the only scientific discipline, that is capable of solving the great challenges of the world—food security, climate change, human health—all of those are biological problems”🦠🧬🧫🌱🍄🐝

Enjoyed chatting with Mark Sullivan at Forbes about the intersection of AI and Biology. 

https://lnkd.in/eZH8EZQ6

Thanks to the The Burn Bag and Andrea Ochoa for a great conversation about biology as a domain of operations, bio-intelligence (BIOINT), and the coming era of biosecurity.

Listen here: bit.ly/49muHGI

Ginkgo Bioworks, Inc.

Are your new product development efforts limited by commercially available enzyme technology? What if you could discover or design the exact enzyme needed to unlock your next innovation? See how one of our customers utilized Ginkgo's scale, automation, and AI algorithms to discover their unique enzyme. 

Interested? Contact us here to learn more! https://hubs.la/Q02jV4hY0

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
average inventory			3.05M -	3.86M 26.70%	2.18M 43.52%
average payables			11.04M -	9.32M 15.59%	9.89M 6.08%
average receivables			87.04M -	116.18M 33.49%	49.81M 57.13%
book value per share		0.31 -	1.11 256.32%	1.03 6.59%	0.68 34.00%
capex per share	-0.01 -	-0.04 160.23%	-0.04 6.75%	-0.03 25.10%	-0.03 18.47%
capex to depreciation	-2.07 -	-4.17 101.88%	-1.94 53.39%	-1.18 39.47%	-0.57 51.54%
capex to operating cash flow	0.50 -	0.43 14.43%	0.22 47.69%	0.21 6.93%	0.14 33.38%
capex to revenue	-0.41 -	-0.75 83.94%	-0.18 76.12%	-0.11 39.24%	-0.16 48.29%
cash per share		0.26 -	1.14 344.52%	0.78 31.25%	0.59 25.06%
days of inventory on hand		63.97 -	9.46 85.21%	7.80 17.57%
days payables outstanding		324.83 -	23.05 92.90%	18.68 18.95%	454.87 2,335.16%
days sales outstanding		115.10 -	174.34 51.46%	63.01 63.86%	24.90 60.47%
debt to assets		0.03 -	0.01 55.84%	0.17 1,467.35%	0.13 23.57%
debt to equity		0.04 -	0.02 58.49%	0.25 1,566.21%	0.20 20.68%
dividend yield
earnings yield	-0.01 -	-0.01 5.73%	-0.16 1,827.54%	-0.74 356.72%	-0.33 55.72%
enterprise value		14.67B -	9.77B 33.36%	1.96B 79.90%	1.99B 1.53%
enterprise value over ebitda		-136.40 -	-5.21 96.18%	-0.90 82.69%	-2.31 156.10%
ev to operating cash flow		-107.97 -	-38.51 64.34%	-7.79 79.77%	-6.75 13.35%
ev to sales		191.31 -	31.14 83.72%	4.11 86.80%	7.93 92.88%
free cash flow per share	-0.05 -	-0.13 189.54%	-0.23 75.01%	-0.18 20.54%	-0.21 15.37%
free cash flow yield	-0.00 -	-0.01 189.54%	-0.03 113.13%	-0.11 290.70%	-0.12 15.37%
graham net net		0.13 -	0.85 549.26%	0.34 59.75%	0.24 29.60%
graham number		0.77 -	5.80 650.99%	5.40 6.85%	2.92 45.94%
income quality	0.37 -	1.07 187.64%	0.14 87.11%	0.12 13.36%	0.33 176.42%
intangibles to total assets	0 -	0.01 Infinity%	0.02 171.85%	0.07 225.15%	0.08 17.51%
interest coverage	-29.57 -	-57.45 94.27%	-770.53 1,241.13%	-20.84K 2,604.53%	9.29K 144.60%
interest debt per share		0.01 -	0.02 43.09%	0.26 1,311.38%	0.14 47.68%
inventory turnover		5.71 -	38.58 576.07%	46.80 21.31%
invested capital		0.04 -	0.02 58.49%	0.25 1,566.21%	0.20 20.68%
market cap	15.03B -	15.03B 0%	11.30B 24.81%	2.84B 74.89%	2.72B 4.26%
net current asset value		221.44M -	1.22B 450.68%	647.03M 46.94%	433.56M 32.99%
net debt to ebitda		3.38 -	0.81 75.97%	0.40 50.76%	0.84 108.63%
net income per share	-0.08 -	-0.09 5.73%	-1.35 1,482.79%	-1.25 7.12%	-0.56 55.72%
operating cash flow per share	-0.03 -	-0.09 204.12%	-0.19 104.07%	-0.15 19.53%	-0.18 22.39%
payables turnover		1.12 -	15.84 1,309.42%	19.54 23.38%	0.80 95.89%
receivables turnover		3.17 -	2.09 33.98%	5.79 176.69%	14.66 153.00%
research and ddevelopement to revenue	1.78 -	2.08 17.27%	3.66 75.76%	2.20 39.85%	2.31 4.79%
return on tangible assets		-0.19 -	-0.91 378.82%	-0.89 1.78%	-0.58 34.54%
revenue per share	0.04 -	0.05 41.48%	0.23 347.10%	0.28 23.28%	0.16 45.02%
roe		-0.27 -	-1.22 344.20%	-1.21 0.57%	-0.81 32.92%
roic		-0.28 -	-1.18 319.39%	-0.85 28.15%	-0.56 33.70%
sales general and administrative to revenue	0.54 -	0.50 8.16%	2.75 450.26%	2.99 8.85%	1.53 48.84%
shareholders equity per share		0.31 -	1.11 256.32%	1.03 6.59%	0.68 34.00%
stock based compensation to revenue	0.01 -	0.01 56.36%	5.12 82,312.23%	4.04 21.02%	0.91 77.38%
tangible asset value		464.90M -	1.52B 227.90%	1.57B 2.66%	965.17M 38.33%
tangible book value per share		0.31 -	1.12 258.10%	0.93 16.85%	0.60 35.58%
working capital		353.32M -	1.59B 349.53%	1.28B 19.59%	837.89M 34.39%

NYSE:DNA

Ginkgo Bioworks Holdings, Inc.

Last Close

0.84

17/05 20:00

Market Cap

2.73B

Beta: 0.89

Volume Today

31.31M

Avg: 18.92M

PE Ratio

−2.78

PFCF: −6.38